Validation and Reliability of the Turkish Version of the Montreal Cognitive Assessment-Basic (MoCA-B) in Individuals With Low Educational Level (MoCA-B Turkish)
Turkish Validity and Reliability Study of the MoCA-B Test
調査の概要
状態
詳細な説明
The prevalence of dementia is steadily increasing, and recognizing cognitive impairment at an early stage-especially during mild cognitive impairment (MCI), before full diagnostic criteria for dementia are met-is crucial. Cognitive screening tools used in individuals with low educational levels often fail to detect MCI. The illiterate version of the Mini-Mental State Examination (MMSE) is insufficient for identifying MCI and early dementia, resulting in delayed diagnosis. The MoCA-Basic (MoCA-B), adapted for low-educated populations and translated into Turkish, has not undergone a validation and reliability study; therefore, it is not routinely used in clinical practice. This study aimed to evaluate the validity and reliability of the Turkish MoCA- B in detecting MCI and dementia, and to compare its diagnostic performance with the MMSE and the Clinical Dementia Rating (CDR).
This study included 55 patients with MCI, 56 with dementia, and 55 healthy controls (total n=166) who presented to the Dementia and Neurology Clinics of Antalya Training and Research Hospital between January 2024 and November 2025. After a detailed mental status examination, participants underwent MoCA-B, MMSE (illiterate version), and CDR assessments. Internal consistency was measured using Cronbach's alpha, and test-retest reliability using the intraclass correlation coefficient (ICC). Group differences were analyzed with one-way ANOVA and Tukey post hoc testing. Correlations between MoCA-B, MMSE, and CDR were evaluated with Pearson correlation. Diagnostic accuracy was assessed through ROC analyses, and optimal cut- off values were determined using the Youden index.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Muratpaşa
-
Antalya、Muratpaşa、トルコ(Türkiye)、07030
- Antalya Training and Research Hospital, Neurology Department, University of Health Sciences (SBÜ), Türkiye
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Age 50-100 years
- Presented with memory complaints and were evaluated in the Neurology/Dementia outpatient clinics of Antalya Training and Research Hospital (Jan 2024-Nov 2025)
- Low educational attainment (illiterate to primary school level)
- Provided informed consent
Exclusion Criteria:
- Active psychiatric disorders / active psychopathology
- Intracranial mass lesions
- Secondary causes of dementia
- Severe medical conditions affecting cognition
- History of traumatic brain injury
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
コントロール
健康管理
|
|
Dementia
Patients who had dementia
|
|
MCI
Patients who had mild cognitive impairment
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
MoCA-B cut off points
時間枠:at baseline and after 4 weeks (test-retest)
|
Calculating cutoff values for dementia and MCI in untrained individuals using the MoCA-B test.
|
at baseline and after 4 weeks (test-retest)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Correlations of MoCA-B total score with MMSE and CDR
時間枠:data were collected between January 2024 and November 2025.
|
As a secondary endpoint, Pearson correlation (level of relationship) of the MoCA-B total score with MMSE and/or CDR total scores was evaluated to demonstrate concurrent criterion validity.
|
data were collected between January 2024 and November 2025.
|
|
Subdomain-level analyses
時間枠:Data were collected between January 2024 and November 2025
|
The subdomain-level analyses for the MoCA-B test aimed to determine which domains best facilitated diagnostic differentiation by evaluating, using ANOVA and post-hoc tests, whether subtest scores such as executive function, memory, and attention differed significantly between control, HKB, and dementia groups.
|
Data were collected between January 2024 and November 2025
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Educational/demographic factors in the use of MoCA-B testing.
時間枠:Data were collected between January 2024 and November 2025
|
The aim of this study was to examine whether the MoCA-B total score and its subgroups are affected not only by disease status but also by characteristics such as years of education, age, gender, marital status, additional illnesses, and family history.
|
Data were collected between January 2024 and November 2025
|
協力者と研究者
捜査官
- スタディチェア:Aylin YAMAN, Prof. MD.、Antalya Training and Research Hospital, Neurology Department, University of Health Sciences (SBÜ), Türkiye
- スタディディレクター:Ali Rıza GÜNDÜZ, MD、Antalya Training and Research Hospital, Neurology Department, University of Health Sciences (SBÜ), Türkiye
出版物と役立つリンク
一般刊行物
- Babacan-Yildiz G, Ur-Ozcelik E, Kolukisa M, Isik AT, Gursoy E, Kocaman G, Celebi A. [Validity and Reliability Studies of Modified Mini Mental State Examination (MMSE-E) For Turkish Illiterate Patients With Diagnosis of Alzheimer Disease]. Turk Psikiyatri Derg. 2016 Spring;27(1):41-6. Turkish.
- Siddiqui M, Nyahoda T, Traber C, Elliott S, Wang V, Toledo-Franco L, Rodin MB. Screening for Cognitive Impairment in Primary Care: Rationale and Tools. Mo Med. 2023 Nov-Dec;120(6):431-439.
- Franzen S; European Consortium on Cross-Cultural Neuropsychology (ECCroN); Watermeyer TJ, Pomati S, Papma JM, Nielsen TR, Narme P, Mukadam N, Lozano-Ruiz A, Ibanez-Casas I, Goudsmit M, Fasfous A, Daugherty JC, Canevelli M, Calia C, van den Berg E, Bekkhus-Wetterberg P. Cross-cultural neuropsychological assessment in Europe: Position statement of the European Consortium on Cross-Cultural Neuropsychology (ECCroN). Clin Neuropsychol. 2022 Apr;36(3):546-557. doi: 10.1080/13854046.2021.1981456. Epub 2021 Oct 6.
- Klil-Drori S, Phillips N, Fernandez A, Solomon S, Klil-Drori AJ, Chertkow H. Evaluation of a Telephone Version for the Montreal Cognitive Assessment: Establishing a Cutoff for Normative Data From a Cross-Sectional Study. J Geriatr Psychiatry Neurol. 2022 May;35(3):374-381. doi: 10.1177/08919887211002640. Epub 2021 Apr 16.
- Carton C, Calafiore M, Cauet C, Messaadi N, Bayen M, Wyts D, Messaadi W, Richebe T, Bayen S. Montreal Cognitive Assessment (MoCA) use in general practice for the early detection of cognitive impairment: a feasibility study. BJGP Open. 2025 Apr 24;9(1):BJGPO.2024.0039. doi: 10.3399/BJGPO.2024.0039. Print 2025 Apr.
- Mulchandani R, Grover U, Ray S, Gandotra S, Dhamija RK, Lyngdoh T. Validating the Telephone Montreal Cognitive Assessment Scale-Hindi as a Remote Screening Tool for Mild Cognitive Impairment. Cogn Behav Neurol. 2025 Jun 1;38(2):35-42. doi: 10.1097/WNN.0000000000000389.
- Avcil, C., H. Bulut, and G. Hızlı Sayar, Psikiyatrik Hastalıklar ve Damgalama. Üsküdar Üniversitesi Sosyal Bilimler Dergisi,
- Scheenen ME, van den Brink RHS, Konstantinidou S, Lugtenburg A, Spit J, Hendriks GJ, Naarding P, de Vent NR, Kessels RPC, Oude Voshaar RC, Jeuring HW. Montreal Cognitive Assessment (MoCA) Norms for Older Patients with a Depressive Disorder. Med Sci (Basel). 2025 Dec 10;13(4):312. doi: 10.3390/medsci13040312.
- Pinto JO, Dores AR, Peixoto B, Barbosa F. Ecological validity in neurocognitive assessment: Systematized review, content analysis, and proposal of an instrument. Appl Neuropsychol Adult. 2025 Mar-Apr;32(2):577-594. doi: 10.1080/23279095.2023.2170800. Epub 2023 Feb 8.
- Atri A, Dickerson BC, Clevenger C, Karlawish J, Knopman D, Lin PJ, Norman M, Onyike C, Sano M, Scanland S, Carrillo M. The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Validated clinical assessment instruments. Alzheimers Dement. 2025 Jan;21(1):e14335. doi: 10.1002/alz.14335. Epub 2024 Dec 23.
- Dickerson BC, Atri A, Clevenger C, Karlawish J, Knopman D, Lin PJ, Norman M, Onyike C, Sano M, Scanland S, Carrillo M. The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care. Alzheimers Dement. 2025 Jan;21(1):e14337. doi: 10.1002/alz.14337. Epub 2024 Dec 23.
- Gugler K, Funk C, Brodelius P. Elicitor-induced tyrosine decarboxylase in berberine-synthesizing suspension cultures of Thalictrum rugosum. Eur J Biochem. 1988 Jan 4;170(3):661-6. doi: 10.1111/j.1432-1033.1988.tb13748.x.
- Malek-Ahmadi M, Nikkhahmanesh N. Meta-analysis of Montreal cognitive assessment diagnostic accuracy in amnestic mild cognitive impairment. Front Psychol. 2024 Feb 13;15:1369766. doi: 10.3389/fpsyg.2024.1369766. eCollection 2024.
- Luo H, Andersson B, Wong GHY, Lum TYS. Longitudinal measurement properties of the Montreal Cognitive Assessment. J Clin Exp Neuropsychol. 2022 Nov;44(9):627-639. doi: 10.1080/13803395.2022.2148634. Epub 2022 Nov 30.
- Luo H, Andersson B, Tang JYM, Wong GHY. Applying Item Response Theory Analysis to the Montreal Cognitive Assessment in a Low-Education Older Population. Assessment. 2020 Oct;27(7):1416-1428. doi: 10.1177/1073191118821733. Epub 2019 Jan 4.
- White RS, Barber JM, Harp JP, Jicha GA. Examining the Effects of Formal Education Level on the Montreal Cognitive Assessment. J Am Board Fam Med. 2022 Dec 23;35(6):1043-1057. doi: 10.3122/jabfm.2022.220093R1.
- Livingston G, Huntley J, Liu KY, Costafreda SG, Selbaek G, Alladi S, Ames D, Banerjee S, Burns A, Brayne C, Fox NC, Ferri CP, Gitlin LN, Howard R, Kales HC, Kivimaki M, Larson EB, Nakasujja N, Rockwood K, Samus Q, Shirai K, Singh-Manoux A, Schneider LS, Walsh S, Yao Y, Sommerlad A, Mukadam N. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024 Aug 10;404(10452):572-628. doi: 10.1016/S0140-6736(24)01296-0. Epub 2024 Jul 31. No abstract available.
- Saleh AA, Alkholy RSAEHA, Khalaf OO, Sabry NA, Amer H, El-Jaafary S, Khalil MAEF. Validation of Montreal Cognitive Assessment-Basic in a sample of elderly Egyptians with neurocognitive disorders. Aging Ment Health. 2019 May;23(5):551-557. doi: 10.1080/13607863.2018.1428936. Epub 2018 Feb 9.
- Huang L, Chen KL, Lin BY, Tang L, Zhao QH, Lv YR, Guo QH. Chinese version of Montreal Cognitive Assessment Basic for discrimination among different severities of Alzheimer's disease. Neuropsychiatr Dis Treat. 2018 Aug 21;14:2133-2140. doi: 10.2147/NDT.S174293. eCollection 2018.
- Amatneeks TM, Hamdan AC. Montreal Cognitive Assessment for cognitive assessment in chronic kidney disease: a systematic review. J Bras Nefrol. 2019 Jan-Mar;41(1):112-123. doi: 10.1590/2175-8239-JBN-2018-0086. Epub 2019 Jan 24.
- Zegarra-Valdivia JA, Chino B, Tituana K, Zapata-Restrepo L, Unaucho MM, Lopez-Norori M, Paredes-Manrique C, Custodio N. Dementia and Mild Cognitive Impairment Identification in Illiterate and Low-Educated People: Systematic Review About the Use of Brief Cognitive Screening Tools. Behav Sci (Basel). 2025 Feb 13;15(2):207. doi: 10.3390/bs15020207.
- Mukadam N, Wolters FJ, Walsh S, Wallace L, Brayne C, Matthews FE, Sacuiu S, Skoog I, Seshadri S, Beiser A, Ghosh S, Livingston G. Changes in prevalence and incidence of dementia and risk factors for dementia: an analysis from cohort studies. Lancet Public Health. 2024 Jul;9(7):e443-e460. doi: 10.1016/S2468-2667(24)00120-8.
- Lwere K, Muwonge H, Sendagire H, Gumikiriza-Onoria JL, Nakimbugwe R, Buwembo D, Nakasujja N, Kaddumukasa M. Cognitive screening and education: assessing the Montreal Cognitive Assessment's validity in older Ugandan populations. Acad Ment Health Well Being. 2025;2(3):10.20935/mhealthwellb7804. doi: 10.20935/mhealthwellb7804. Epub 2025 Jul 18.
便利なリンク
- Güngen, C., Ertan, T., Eker, E., Yaşar, R., & Engin, F. (2002). Standardize Mini Mental Test'in Türk Toplumunda Hafif Demans Tanısında Geçerlik ve Güvenilirliği. Türk Psikiyatri Dergisi, 13(4), 273-281.
- Official data from the Turkish Statistical Institute's research on the profile of the elderly in Türkiye.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2024-018
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。